MedTrace Logo

Rectal Dexmedetomidine Niosomes for Postoperative Analgesia in Pediatric Cancer Patients.

NCT05340725 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2023-01-23

No results posted yet for this study

Summary

Applying nanotechnology in drug delivery systems improved the bioavailability and kinetic profile of drugs in biological systems

Conditions

  • Postoperative Pain

Interventions

DRUG

DEX-IV

patients will receive iv DEX 1µ/kg diluted in 100 ml saline and given slowly iv infusion over 10 min. 30 min. before induction of anesthesia.

DRUG

DEX-Rectal

Patients will receive rectal DEX suppository formulation at approximately 1µ/kg at 30 min. before induction of anesthesia

DRUG

DEX-Nano-Rectal

Patients will receive rectal DEX suppository in the Niosomes formulation at approximately 1µ/kg at 30 min. before induction of anesthesia

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Hala Abdel-Ghaffar, MD · Professor of anesthesia and intensive care, faculty of medicine, Assiut university, Assiut, Egypt.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
7 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2023-12-01
Completion
2023-12-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05340725 on ClinicalTrials.gov